1. Aegis Logistics:

This oil and gas company has surged 25% over the past week after JM Financial issued a positive outlook and set a target price of Rs 1,200. The brokerage cited stronger-than-expected performance in the LPG distribution segment, which accounts for more than 90% of the revenue. The stock also appears in a screener of companies where foreign institutional investors are increasing their shareholding.

Recent gains follow the March-quarter LPG distribution volume, which rose 71% YoY. Expansion beyond Mumbai and Kandla facilities drove this growth. Aegis now distributes gas from multiple locations, including Mangalore, Haldia and Pipavav.

FY26 net profit came in 25% above Forecaster estimates. High realisations of Rs 7,000 per tonne boosted profit growth over historical levels of Rs 4,000. CFO Murad Moledina said higher energy prices and shipping fares boosted margins. He believes these levels will be sustainable in a normalised environment as volumes continue to rise.

The company remains on track to achieve its target of 2 million tonnes of gas distribution by 2028, from its current capacity of less than a million tonnes. Moledina added that ammonia distribution would contribute to this target, while generating margins of about Rs 5,000 per tonne.

Aegis Logistics plans to invest $5 billion through FY31. The firm expects to spend $1.2 billion this fiscal year and $600 million in FY28. These funds will support several projects scheduled for commissioning by September this year, including liquid storage capacity at Mumbai port and the JNPA terminal expansion.

Management expects to deploy 60% of the planned capex between FY29 and FY31. Project execution, funding and leverage remain key developments to watch. Motilal Oswal maintains a “Neutral” outlook as it believes current valuations factor in capacity expansion and earnings.

2. Zen Technologies:

This defence technology provider surged 7.2% on June 4 following reports that the Indian government is eyeing a massive Rs 20,000 crore drone procurement order. While Zen Tech makes anti-drone systems and training simulators, investors see a major long-term opportunity, as a larger drone fleet will likely increase demand for pilot training simulators and counter-drone systems.

Adding to the positive sentiment, Zen Tech closed FY26 with a strong order book of Rs 1,336 crore, providing revenue visibility for the coming quarters. The company secured new order inflows worth Rs 431 crore in Q4FY26 alone, driven by ongoing indigenous defence manufacturing initiatives. On order execution, CFO Hari Haran Chalat said, “Out of the total order book, Rs 1,000 crore is expected to be executed, and most of the deliveries are going to happen in Q2 and Q3 of FY27.”

Despite this, FY26 financial performance remained weak. Net profit declined 31%, while revenue fell 25%. Management attributed the weakness to slower execution of existing orders and delays in converting opportunities into firm contracts. Trendlyne Forecaster estimates suggest revenue and net profit could grow 72.9% and 85.7%, respectively, in FY27.

Management expects to generate cumulative revenue of Rs 4,000 crore across FY27 and FY28. Growth is anticipated to be driven by the execution of delayed FY26 orders and expansion into newer defence segments such as combat robotics, interceptor drones and automated weapon systems.

ICICI Direct recommends a ‘Buy’ rating on the stock with a price target of Rs 1,900, noting that the company will benefit from growing demand for anti-drone systems and defence simulators. It expects that the global training and simulation market, which is at $14 billion, could reach $20 billion by 2032, while the anti-drone market is projected to expand from $3 billion to $14 billion over the same period. 

3. Apar Industries:

This electrical equipment manufacturer rose 3.5% on June 10 after the company’s management gave a positive outlook on the business. CEO & MD Kushal Desai said, “If everything goes well, then we should be seeing double our profits in the next four to five years.” Apar is betting on rising investments in power transmission, renewable energy and data centres to drive growth.

Apar’s cables business is expected to play a major role in that expansion. The company is targeting 25% annual growth in its cables business and plans to invest around Rs 1,500 crore in capex for FY27. More than half of this will go toward expanding cable manufacturing capacity.

In FY26, revenue grew 23.3% to Rs 22,902 crore, led by strong demand for conductors and cables across power transmission and renewable energy projects. Net profit rose 18.9%, supported by higher volumes, improving exports and a greater contribution from premium products.

Conductors, which account for 55.5% of Apar's revenue, remained the company's biggest business. Revenue here grew 32.7% during FY26 as utilities invested in renewable energy projects, transmission upgrades and grid modernisation. Premium products contributed 45.8% of conductor revenue compared with 40.6% a year ago.

The US is emerging as another growth driver for Apar, with revenue from the market rising nearly 50% during the year. Desai said the US market is seeing strong traction, led by growing demand from data-centre projects. “We've already supplied cables worth around $15 million to three major data-centre projects in the US,” he added.

PL Capital reiterated its ‘Hold’ call on the stock as it expects Apar to benefit from long-term demand linked to renewable energy, grid modernisation and data-centre expansion. The brokerage also highlighted the company’s growing US business, rising share of premium conductors and strong order visibility in conductors and cables as key drivers for future growth. 

4. Ajanta Pharma:

The stock of this pharmaceutical company jumped more than 6% over the past week, driven by a fresh policy push from the government. India’s Pharmaceutical Secretary, Manoj Joshi, announced an upcoming scheme aimed at boosting the bulk drugs sector. 

Unlike traditional production-linked incentive programs, the new initiative will focus on strengthening long-term manufacturing capacity, promoting R&D investment, and fostering closer collaboration between industry and academia.

Adding to the momentum, a promoter entity of Ajanta Pharma sold 34.5 lakh shares worth over Rs 1,024 crore through a block deal on June 9. The stake was bought by institutional investors, including Kotak Mahindra Mutual Fund and Aditya Birla Sun Life Mutual Fund. The transaction underscored institutional confidence in the company, supported by its robust earnings momentum and healthy profit margins. The stock features on a screener of companies that have outperformed their respective industries over the past month.

While shipping chaos in the Middle East disrupted global logistics, Ajanta’s domestic market and US generic business stepped up to secure its FY26 performance. Revenue jumped 18.6% to Rs 5,624.9 crore, powered by a better product mix and a stellar US run, backed by 8 new product launches over the last 15 months. Net profit rose 14.7% to Rs 1,056 crore, driven by gains in market share across its existing product portfolio.

Managing Director Yogesh Agrawal guided for mid-single-digit growth in the US market for FY27, supported by strong sales of the company’s seasonal flu drug. He remains confident of sustaining a robust EBITDA margin of around 27%, with a possible variation of up to 1%. On the international front, Ajanta is preparing to enter the rapidly growing weight-loss market by filing for generic semaglutide in emerging markets, with regulatory approvals expected within the following 12 to 18 months.

ICICI Direct maintained its ‘Buy’ rating on the stock with a target price of Rs 3,520, praising Ajanta as one of the market’s most reliable and consistent free cash flow generators. This financial strength is backed by highly disciplined spending. For FY27, management has budgeted Rs 400 crore in capex, earmarking Rs 150 crore for routine maintenance and the remainder for future growth initiatives.

5. Concord Biotech: 

This biotechnology stock surged 9.3% over the past week after the company received two approvals from the US FDA. The company received approval for its Mycophenolate Mofetil oral suspension on June 3. The drug is used to prevent organ rejection and addresses an estimated US market of $30 million. The FDA also approved Tofacitinib tablets for the treatment of adult patients with arthritis, spondylitis and colitis, with a US market of $500 million.

The drugmaker reported weak earnings in FY26. Revenue declined 11%, while net profit dropped 30%. Geopolitical challenges, regulatory delays, changing customer purchasing patterns and internal setup costs weighed on performance. Both revenue and net profit missed Forecaster estimates. The active pharmaceutical ingredients (API) and formulations segments contracted during the fiscal year as orders from the US slowed during the first half of FY26. Potential customers also avoided changing existing supply chains amid uncertainty over US tariffs.

The company also faced challenges in obtaining approvals from the Central Drugs Standard Control Organisation, which affected deliveries to Europe for nearly three months. Management suspended a major tender in the Middle East due to regional geopolitical conflicts, which resulted in lower turnover. API deliveries to the area also slowed down, causing exports to drop by 9% during the year.

Management expects a recovery despite the underperformance. Concord’s Joint MD & CEO, Ankur Vaid, said, “We guide for revenue growth slightly better than our historical average of 18% in FY27.” He adds that new ventures, like the injectable facility and the overseas subsidiary, will likely break even in the next financial year.

Following the earnings release, Jefferies maintained a ‘Hold’ rating on the stock, with a target price of Rs 1,020 per share. The brokerage noted that the FY26 performance fell short of expectations due to delayed order execution and regulatory hurdles. However, analysts highlight that the robust order book provides near-term revenue growth visibility and potential for EBITDA margin improvement.

Trendlyne's analysts identify stocks that are seeing interesting price movements, analyst calls, or new developments. These are not buy recommendations.